Tuberculosis – Pipeline Review, H1 2012

Document Sample
Tuberculosis – Pipeline Review, H1 2012 Powered By Docstoc
					                       Tuberculosis – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1814IDB
                                                                                           Publication Date: February 2012




Tuberculosis – Pipeline Review, H1 2012                                                    GMDHC1814IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Tuberculosis – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 14
    List of Figures .............................................................................................................................................................................. 15
Introduction....................................................................................................................................................................................... 16
    Global Markets Direct Report Coverage ...................................................................................................................................... 16
Tuberculosis Overview ..................................................................................................................................................................... 17
Therapeutics Development............................................................................................................................................................... 18
    An Overview of Pipeline Products for Tuberculosis ..................................................................................................................... 18
Tuberculosis Therapeutics under Development by Companies ....................................................................................................... 20
Tuberculosis Therapeutics under Investigation by Universities/Institutes ......................................................................................... 24
Late Stage Products ......................................................................................................................................................................... 28
    Comparative Analysis .................................................................................................................................................................. 28
Mid Clinical Stage Products.............................................................................................................................................................. 29
    Comparative Analysis .................................................................................................................................................................. 29
Early Clinical Stage Products ........................................................................................................................................................... 30
    Comparative Analysis .................................................................................................................................................................. 30
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 31
    Comparative Analysis .................................................................................................................................................................. 31
Tuberculosis Therapeutics – Products under Development by Companies ..................................................................................... 32
Tuberculosis Therapeutics – Products under Investigation by Universities/Institutes....................................................................... 36
Companies Involved in Tuberculosis Therapeutics Development .................................................................................................... 41
    Johnson & Johnson ..................................................................................................................................................................... 41
    Sequella, Inc. ............................................................................................................................................................................... 42
    AstraZeneca PLC ........................................................................................................................................................................ 43
    GlaxoSmithKline plc .................................................................................................................................................................... 44
    Emergent BioSolutions Inc. ......................................................................................................................................................... 45
    Nanotherapeutics, Inc.................................................................................................................................................................. 46
    Achillion Pharmaceuticals, Inc. .................................................................................................................................................... 47
    Pfizer Inc...................................................................................................................................................................................... 48
    Crucell N.V. ................................................................................................................................................................................. 49
    Intercell AG .................................................................................................................................................................................. 50
    Lupin Limited ............................................................................................................................................................................... 51
    Summit Corporation plc ............................................................................................................................................................... 52
    PolyMedix, Inc. ............................................................................................................................................................................ 53
    Immune Network Research Ltd. .................................................................................................................................................. 54
    Snowdon Inc. ............................................................................................................................................................................... 55
    Recipharm AB ............................................................................................................................................................................. 56
    ApoImmune, Inc. ......................................................................................................................................................................... 57
    Mondobiotech Holding AG ........................................................................................................................................................... 58
    Archivel Farma S.L. ..................................................................................................................................................................... 59
    Avir Green Hills Biotechnology AG .............................................................................................................................................. 60
    TVAX Biomedical, LLC ................................................................................................................................................................ 61



Tuberculosis – Pipeline Review, H1 2012                                                                                                     GMDHC1814IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Tuberculosis – Pipeline Review, H1 2012




    Medisyn Technologies, Inc. ......................................................................................................................................................... 62
    TB Alliance .................................................................................................................................................................................. 63
    Vakzine Projekt Management GmbH .......................................................................................................................................... 64
    ISA Pharmaceuticals B.V. ........................................................................................................................................................... 65
Tuberculosis – Therapeutics Assessment ........................................................................................................................................ 66
    Assessment by Monotherapy Products ....................................................................................................................................... 66
    Assessment by Combination Products ........................................................................................................................................ 67
    Assessment by Route of Administration ...................................................................................................................................... 68
    Assessment by Molecule Type .................................................................................................................................................... 70
Drug Profiles..................................................................................................................................................................................... 73
    OPC-67683 - Drug Profile ........................................................................................................................................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    SND-159 - Drug Profile................................................................................................................................................................ 74
        Product Description................................................................................................................................................................. 74
        Mechanism of Action ............................................................................................................................................................... 74
        R&D Progress ......................................................................................................................................................................... 74
    NanoGENT - Drug Profile ............................................................................................................................................................ 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    PMX-10072 - Drug Profile ........................................................................................................................................................... 76
        Product Description................................................................................................................................................................. 76
        Mechanism of Action ............................................................................................................................................................... 76
        R&D Progress ......................................................................................................................................................................... 76
    TMC 207 - Drug Profile ................................................................................................................................................................ 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress ......................................................................................................................................................................... 77
    SQ 109 - Drug Profile .................................................................................................................................................................. 79
        Product Description................................................................................................................................................................. 79
        Mechanism of Action ............................................................................................................................................................... 79
        R&D Progress ......................................................................................................................................................................... 79
    MVA85A - Drug Profile ................................................................................................................................................................ 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 82
    Vaccine For Tuberculosis - Drug Profile ...................................................................................................................................... 85
        Product Description................................................................................................................................................................. 85
        Mechanism of Action ............................................................................................................................................................... 85
        R&D Progress ......................................................................................................................................................................... 85
    ApoVax104-TB Vaccine - Drug Profile ........................................................................................................................................ 86
        Product Description................................................................................................................................................................. 86


Tuberculosis – Pipeline Review, H1 2012                                                                                                   GMDHC1814IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Tuberculosis – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................... 86
        R&D Progress ......................................................................................................................................................................... 86
    Rifalazil - Drug Profile .................................................................................................................................................................. 87
        Product Description................................................................................................................................................................. 87
        Mechanism of Action ............................................................................................................................................................... 87
        R&D Progress ......................................................................................................................................................................... 87
    SQ609 - Drug Profile ................................................................................................................................................................... 89
        Product Description................................................................................................................................................................. 89
        Mechanism of Action ............................................................................................................................................................... 89
        R&D Progress ......................................................................................................................................................................... 89
    SQ641 - Drug Profile ................................................................................................................................................................... 91
        Product Description................................................................................................................................................................. 91
        Mechanism of Action ............................................................................................................................................................... 91
        R&D Progress ......................................................................................................................................................................... 91
    NasL3/HtkBCG (BCG Adjuvant) - Drug Profile ............................................................................................................................ 93
        Product Description................................................................................................................................................................. 93
        Mechanism of Action ............................................................................................................................................................... 93
        R&D Progress ......................................................................................................................................................................... 93
    MTBVAC01 - Drug Profile ........................................................................................................................................................... 94
        Product Description................................................................................................................................................................. 94
        Mechanism of Action ............................................................................................................................................................... 94
        R&D Progress ......................................................................................................................................................................... 94
    PNU-100480 - Drug Profile .......................................................................................................................................................... 95
        Product Description................................................................................................................................................................. 95
        Mechanism of Action ............................................................................................................................................................... 95
        R&D Progress ......................................................................................................................................................................... 95
    VPM1002 - Drug Profile ............................................................................................................................................................... 96
        Product Description................................................................................................................................................................. 96
        Mechanism of Action ............................................................................................................................................................... 96
        R&D Progress ......................................................................................................................................................................... 96
    HG85 A/B - Drug Profile .............................................................................................................................................................. 97
        Product Description................................................................................................................................................................. 97
        Mechanism of Action ............................................................................................................................................................... 97
        R&D Progress ......................................................................................................................................................................... 97
    Hsp DNA Vaccine - Drug Profile .................................................................................................................................................. 98
        Product Description................................................................................................................................................................. 98
        Mechanism of Action ............................................................................................................................................................... 98
        R&D Progress ......................................................................................................................................................................... 98
    VecFlu - Drug Profile ................................................................................................................................................................... 99
        Product Description................................................................................................................................................................. 99
        Mechanism of Action ............................................................................................................................................................... 99
        R&D Progress ......................................................................................................................................................................... 99
    PS-conjugate - Drug Profile ....................................................................................................................................................... 100
        Product Description............................................................................................................................................................... 100


				
DOCUMENT INFO
Description: Tuberculosis - Pipeline Review, H1 2012', provides an overview of the Tuberculosis therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tuberculosis. 'Tuberculosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries